On February 8, the Federal Circuit issued a stay of the permanent injunction granted against the sale of Sanofi and Regeneron’s Praluent® (alirocumab).  The injunction was to have become effective on February 21, 2017, but as a result of the stay, the companies can continue marketing, selling and manufacturing Praluent® pending the appeal of the injunction order.

Sanofi and Regeneron issued a press release announcing the decision, which can be found here.